



**Duke Human Vaccine Institute**

Duke University School of Medicine

# **Safety of Adjuvanted versus High-Dose Inactivated Influenza Vaccines in Older Adults: Preliminary Safety Results**

ClinicalTrials.gov Identifier NCT03183908

Kenneth Schmader, MD

Duke University Medical Center

ACIP Meeting

February 26, 2020





## Sponsor and Collaboration

This work was supported by the Centers for Disease Control and Prevention (CDC) through the Clinical Immunization Safety Assessment (CISA) Project

- Duke University Medical Center (Lead Site)
- Boston University Medical Center (Contributing Site)
- Cincinnati Children's Hospital Medical Center (Contributing Site, Boston University sub-contract)

## Disclaimer

The findings and conclusions in this presentation are those of the presenter and do not necessarily represent the official position of the Centers for Disease Control and Prevention

# Acknowledgments

## Duke University Medical Center

- Dr. Ken Schmader (PI)
- Dr. Chip Walter (Co-PI)
- Chris Todd (Program Manager)
- Kristen Gunnell (Program Manager)
- Wes Rountree (Principal Biostatistician)
- Marek Poniewierski (Biostatistician)
- Sue Doyle
- Joyce Gandee

## Boston Medical Center

- Dr. Elizabeth Barnett (PI)
- Dr. Christine Liu (Investigator)
- Dr. Heidi Auerbach (Investigator)
- Anisha Bhanot



## CDC

- Dr. Theresa Harrington (PI)
- Dr. Karen Broder (Sub-PI)
- Dr. Patricia Wodi
- Dr. Lisa Grohskopf
- Dr. Brendan Flannery
- Dr. Pedro Moro
- Dr. Tom Shimabukuro
- Oidda Museru

## Cincinnati Children's Hospital Medical Center

- Dr. Elizabeth Schlaudecker (PI)
- Dr. Mary Staat
- Nancy Back

# Study Background and Significance

- To prevent influenza in older persons, ACIP\* recommends vaccination with any U.S.-licensed, age-appropriate influenza vaccine
- Trivalent high dose (HD-IIV3; Fluzone® High-Dose) and adjuvanted (aIIV3; FLUAD®) influenza vaccines are licensed for use only in persons aged 65 years and older in the U.S. and may have improved effectiveness compared to SD-IIV3\*\*
- The safety of HD-IIV3 and aIIV3 has not been compared directly in the same clinical trial in the United States
- The relative impact of HD-IIV3 and aIIV3 reactions on health-related quality of life (HRQOL) has not been studied.

\*ACIP: Advisory Committee on Immunization Practices

\*\*SD-IIV3: Trivalent inactivated influenza vaccine, standard dose

# Study Objectives: Primary

1. To compare the proportions of moderate-severe injection-site pain after aIIV3 and HD-IIV3

*Research hypothesis: the proportion of subjects who have moderate-severe injection-site pain within the first week post-vaccination will be noninferior (not higher) for aIIV3 (newer U.S. vaccine) compared to HD-IIV3*

2. To compare serious adverse events (SAE) and adverse events of clinical interest (AECI) after aIIV3 and HD-IIV3 in the study population and by age-group (65-79 years and  $\geq 80$  years)

## Study Objectives: Secondary

1. To compare the proportions of local and systemic reactions (other than moderate-severe injection-site pain) after aIIV3 and HD-IIV3 in the full study population and by age group (65-79 years and  $\geq 80$  years).
2. To describe and compare change in health-related quality of life (HRQOL) after aIIV3 and HD-IIV3 in the full study population and by age group.

# Study Design and Participants

- Design
  - Randomized, blinded clinical trial of aIIV3 versus HD-IIV3 during the 2017-2018 and 2018-2019 influenza seasons
- Setting
  - Duke University (2017-2019), Boston University (2017-2019), Cincinnati Children's Hospital Medical Center (2018-2019)
- Participants
  - Community-dwelling volunteers aged  $\geq 65$  years
  - Not immunosuppressed, cognitively intact, no co-vaccination, no influenza vaccine contraindications
    - Goal to enroll  $\geq 20\%$  aged  $\geq 80$  years
- Intervention
  - Randomized 1:1 to 0.5 ml IM dose of aIIV3 or HD-IIV3
    - Stratified by age group (65-79) and ( $\geq 80$ ) years

# Safety and Reactogenicity Assessment

- Participants monitored in clinic  $\geq 15$  minutes post-vaccination for adverse events, including syncope
- Solicited reactogenicity events and unsolicited adverse events assessed using standard symptom diary Day 1 (vaccination day) through Day 8
- SAEs during Day 1 through Day 43 post-vaccination
- Adverse events of clinical interest (AECI)
  - Syncope during clinic post-vaccination monitoring
  - Anaphylaxis in first 24 hours after vaccination
  - Guillain-Barré syndrome within 43 days post-vaccination
  - New onset immune-mediated conditions within 43 days post-vaccination



# Health-Related Quality of Life (HRQOL) Assessments

- EuroQOL-5 dimensions-5 levels: EQ-5D-5L\*
  - Mobility, self-care, usual activities, pain/discomfort and anxiety/depression rated on 5 levels:
    - no problems, slight problems, moderate problems, severe problems, and extreme problems
  - Responses converted to a Utility Index summary measure
  - Ranges from -0.109 (worst health) to 1.000 (best health)
- EuroQol-Visual Analogue Scale: EQ-VAS
  - Self-rated health on 0 – 100 scale

\*Herdman M, et al. Qual Life Res 2011;20:1727-36.

# Analysis Plan – Safety Sample Size

- 668 participants (334 per group)
  - Assumes 5% of older adults have moderate-severe injection-site pain after aIIV3 or HD-IIV3 based on prelicensure studies\*
  - Clinically meaningful noninferiority margin of 5%
  - alpha of 0.025 (one-sided)
  - At least 80% power to demonstrate proportion of moderate-severe pain noninferior after aIIV3 vs. HD-IIV3

[\\*https://www.fda.gov/media/94583/download](https://www.fda.gov/media/94583/download)

[\\*https://www.fda.gov/media/119870/download](https://www.fda.gov/media/119870/download)


# Analysis Plan

## Statistical Tests

- Reactogenicity Outcomes
  - Moderate-severe injection-site pain (primary)
    - one-sided alpha 0.025 level
    - Upper bound of a stratified by site Newcombe binomial confidence interval
    - Noninferiority margin of 5%
  - Other moderate-severe reactions: one sided alpha 0.01 level to adjust for multiple comparisons, otherwise used same statistical tests as above
- SAEs and AECIs (primary): two-sided alpha 0.05 level, 95% exact binomial confidence interval
- Change in HRQOL day 1 to day 3 (secondary): two sided alpha 0.01 level to adjust for multiple comparisons, Mann-Whitney U tests

# Results

# Study Consort Diagram\*



\*Full Analysis Population 2: all subjects who were randomized and vaccinated

\*Full Analysis Population 1: all subjects who were randomized, vaccinated, and provided at least one day of complete data on the symptom diary form.

## Summary of Participants Enrolled and Randomized By Site

Site	All Ages	65-79 Years	≥80 Years
Duke	428	349	79
Boston	243	215	28
Cincinnati	86	30	56
Total	757	594	163
Percentage	100%	78.5%	21.5%

# Demographic Characteristics

Characteristic	allV3 (N=378)	HD-IIV3 (N=379)
	Median (Range) or N (%)	Median (Range) or N (%)
Age in Years	72 (65 - 96)	72 (65 - 97)
65-79 years	298 (78.8)	296 (78.1)
≥80 years	80 (21.2)	83 (21.9)
Sex		
Female	213 (56.3)	207 (54.6)
Male	165 (43.7)	172 (45.4)
Race		
White Only	286 (75.7)	303 (79.9)
Black Only	70 (18.5)	59 (15.6)
Other*	22 (5.8)	17 (4.5)
Ethnicity: Hispanic or Latino	7 (1.9)	1 (0.3)

\*American Indian/Alaskan Native, Asian, More Than One Race

# Primary Outcome (1) Results

## Injection-Site Pain

Group	None	Mild	Moderate	Severe	<b>Mod-Severe</b>
allV3	297 (78.6%)	69 (18.3%)	10 (2.7%)	2 (0.5%)	<b>12 (3.2%)</b>
HD-IIV3	282 (74.8%)	73 (19.4%)	21 (5.6%)	1 (0.3%)	<b>22 (5.8%)</b>

Moderate-Severe Pain Difference for allV3 minus HD-IIV3 = -2.7%  
95% Confidence Interval (-5.8% to 0.36%)

Upper limit of the 95% CI of the difference for allV3 minus HD-IIV3 was 0.36% and the noninferiority margin was 5%

The proportion of participants with moderate-severe injection-site pain after allV3 was noninferior (not higher) than the proportion after HD-IIV3




## Primary Outcome (2) Results

### Serious Adverse Events (SAEs) and Adverse Events of Clinical Interest (AECI)

- No SAE was determined to be related to vaccination
- No significant difference in proportion of SAEs between vaccine groups
  - 9 participants had  $\geq 1$  SAE after aIIV3 (2.4%; 95% CI: 1.1, 4.5)
  - 3 participants had  $\geq 1$  SAE after HD-IIV3 (0.8%; 95% CI 0.2, 2.2).
- No AECI occurred

# Primary and Secondary Outcome (1) Results

## Proportions of Moderate-Severe Local Reactions after aIIV3 and HD-IIV3<sup>§</sup>




<sup>§</sup>No local reactions led to a medical visit

\*Noninferiority criteria were not met for aIIV3

# Secondary Outcome (1) Results

## Proportions of Moderate-Severe Systemic Reactions after aIIV3 and HD-IIV3<sup>§</sup>



<sup>§</sup>No systemic reactions led to a medical visit

\*Noninferiority criteria were not met for aIIV3

# EQ-5D-5L and EQ-VAS Between Group Analysis

## Change in Score From Day 1 Pre-vaccination to Day 3 Post-vaccination

### EQ-5D-5L

Group	Mean Day 1	Mean Day 3	Difference (95% CI)
allV3	0.89	0.95	-0.05 (-0.06, -0.04)
HD-IIV3	0.90	0.95	-0.05 (-0.06, -0.04)

No Significant Between Group Difference:  
allV3 -0.05 vs. HD-IIV3 -0.05,  $p = 0.74$

### EQ-VAS

Group	Mean Day 1	Mean Day 3	Difference (95% CI)
allV3	85.5	88.1	-2.22 (-3.38, -1.06)
HD-IIV3	85.8	88.3	-2.45 (-3.45, -1.54)

No Significant Between Group Difference:  
allV3 -2.22 vs. HD-IIV3 -2.45,  $p = 0.79$

# Summary

- The proportion of participants with moderate-severe injection-site pain was not higher after aIIV3 than HD-IIV3
- There were no vaccine-related SAE
- The short-term post-vaccination HRQOL was not affected by either vaccine.
- The safety findings in our study were consistent with prelicensure data for aIIV3 and HD-IIV3.
- From the standpoint of safety, either vaccine is an acceptable option for the prevention of influenza in older adults.